These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Friedlaender MH; Howes J Am J Ophthalmol; 1997 Apr; 123(4):455-64. PubMed ID: 9124242 [TBL] [Abstract][Full Text] [Related]
27. Persistence of increased Eotaxin-1 (CCL11) level in tears of patients wearing contact lenses: a long-term follow-up study. Tran HV; Eperon S; Guex-Crosier Y Klin Monbl Augenheilkd; 2011 Apr; 228(4):326-9. PubMed ID: 21484639 [TBL] [Abstract][Full Text] [Related]
28. Immune responses in monkeys to lenses from patients with contact lens induced giant papillary conjunctivitis. Ballow M; Donshik PC; Rapacz P; Maenza R; Yamase H; Muncy L CLAO J; 1989; 15(1):64-70. PubMed ID: 2917401 [TBL] [Abstract][Full Text] [Related]
29. Giant papillary conjunctivitis in contact lens wearers. Allansmith MR; Korb DR; Greiner JV; Henriquez AS; Simon MA; Finnemore VM Am J Ophthalmol; 1977 May; 83(5):697-708. PubMed ID: 868969 [TBL] [Abstract][Full Text] [Related]